Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

PRAX

Phase 2b

PRAX-628

Focal onset seizures (FOS) or epilepsy

H1 2025

RADIANT: 8/13/24 Efficacy study start in H2 2024 & topline results in H1 2025.

Data readout

CRDF

Phase 2

Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab)

Metastatic colorectal cancer (mCRC)

H1 2025

CRDF-004 trial w/ Pfizer Ignite. 02/29/24- First patient dosed. 12/10/24- Initial data reported. 2/27/25- Additional clinical data in H1 2025.

Data readout

TRML

Phase 2

Pacibekitug (TOUR006)

CKD and elevated hs-CRP

Q2 2025

TRANQUILITY trial. 4/24- Trial initiated. 5/16/24- First patient dosed. 8/5/24- Poster presentation at CMHC '24. 3/13/25- Topline data in Q2 2025.

Data Readout

VRCA

Phase 2

VP-315

Basal Cell Carcinoma

H1 2025

8/14/24- Part 2 topline results reported. 1/21/25- Prelim topline results at Winter Dermatology Conf '25. 3/11/25- Genomic and immune response data in H1 2025 and receive EoPh2 meeting minutes from FDA.

Data readout

LYRA

Phase 3

LYR-210 (anti-inflammatory implantable drug matrix)

CR (Chronic Rhinosinusitis) (Surgically Naïve Patients)

Q2 2025

ENLIGHTEN 1 & 2 trials. 8/29/23- ENLIGHTEN 1 completed enrollment. 10/15/24- Enrollment complete in ENLIGHTEN 2. 11/13/24- ENLIGHTEN 1 extension study data reported. 3/13/25- ENLIGHTEN 2 topline data in Q2 2025.

Data readout

FBIO

PDUFA

CUTX-101 (Copper Histidinate)

Menkes Disease

June 30, 2025

W/ Cyprium. Rolling NDA submission is ongoing. 12/06/23- Completes asset to Sentynl Therapeutics, a subsidiary of Zydus Lifesciences. Retains 100% ownership over any FDA review that may be issued at NDA approval. 1/6/24- FDA accepted NDA w/ PDUFA action date set for June 30, 2025.

Approval decision

ACET

Phase 1

ADI-001 (allogeneic CAR gamma-delta T cell therapy)

Lupus Nephritis

H1 2025

Suspected Big Mover: 6/5/24- Initiate study within June 2024. 11/18/24- Ongoing enrollment for LN. Prelim LN data in H1 2025. SLE, SSc, IIM, & SPS enrollment in Q1 2025; ANCA, AAV in H2 2025.

Data readout

RXRX

Phase 2

REC-4881

Familial Adenomatous Polyposis

H1 2025

TUPELO trial. 11/6/24- Part 1 completed and Part 2 enrollment ongoing. Safety and preliminary efficacy data in H1 2025.

Data Readout

VERV

Phase 1b

VERVE-102 (PCSK9)

Heterozygous Familial Hypercholesterolemia (HeFH)

Q2 2025

Heart-2 trial. 4/2/24- CTA cleared by U.K, Australia & Canada. 5/7/24- First patient dosed. Actively enrolling patients. 1/13/25- Initial data in Q2 2025 & initiate Ph2 trial in H2 2025. 3/24/25- FDA cleared IND.

Data readout

GYRE

Phase 3

F351 (Hydronidone)

Chronic Hepatitis B Liver Fibrosis

Q2 2025

Trial in China. 10/22/24- Last patient completed. 3/17/25- Topline data in Q2 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20